Skip Navigation



Japanese Journal of Clinical Oncology Advance Access published online on August 19, 2008
Japanese Journal of Clinical Oncology, doi:10.1093/jjco/hyn081
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
38/9/634    most recent
hyn081v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Sasaki, T.
Right arrow Articles by Hiratsuka, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sasaki, T.
Right arrow Articles by Hiratsuka, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author (2008). Published by Oxford University Press. All rights reserved

Possible Relationship Between the Risk of Japanese Bladder Cancer Cases and the CYP4B1 Genotype

Takamitsu Sasaki1, Miho Horikawa2, Kazuhiko Orikasa3, Makoto Sato4, Yoichi Arai3, Yoshitaka Mitachi1, Michinao Mizugaki2, Masaaki Ishikawa1 and Masahiro Hiratsuka1

1 Department of Clinical Pharmacotherapeutics
2 Department of Clinical Pharmaceutics, Tohoku Pharmaceutical University, Sendai
3 Department of Urology, Tohoku University, Sendai
4 Department of Urology, Senen General Hospital, Tagajyo, Miyagi, Japan

For reprints and all correspondence: Masahiro Hiratsuka, Department of Clinical Pharmacotherapeutics, Tohoku Pharmaceutical University, 4-4-1, Komatsushima, Aoba-ku, Sendai 981-8558, Japan. E-mail: mhira{at}tohoku-pharm.ac.jp

Received May 14, 2008; accepted July 17, 2008

Cytochrome P450 4B1 (CYP4B1) is involved in the metabolism of several xenobiotics, such as 2-aminofluorene, 2-naphthylamine and benzidine. CYP4B1 allelic variants CYP4B1*1–*7 were recently identified. We thus hypothesized that CYP4B1 genotypes may modify bladder cancer risk. We examined the CYP4B1 genotypes in 169 bladder cancer cases and 190 hospital controls using a hybridization probe assay. Among the CYP4B1 genotypes observed, the most frequent genotypes in both the groups were CYP4B1*1/*1, *1/*2, *1/*3 and *2/*2. Logistic regression analysis revealed that the subjects carrying the CYP4B1*1/*2 or *2/*2 genotypes had a 1.75-fold increased risk of bladder cancer (95% CI=1.03–2.95, P = 0.038) compared with the subjects carrying the CYP4B1*1/*1 genotype. We demonstrated the first genetic study regarding the association of CYP4B1 with bladder cancer. Our results suggest that CYP4B1 genotypes might have an effect on the risk of bladder cancer.

Key Words: CYP4B1 • genotype • bladder cancer


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.